July 27, 2020 / 11:23 AM / 17 days ago

Emergent signs $174 million deal to make AstraZeneca's potential COVID-19 vaccine

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

(Reuters) - Emergent BioSolutions Inc (EBS.N) said on Monday it signed a $174 million (135 million pounds) agreement with AstraZeneca (AZN.L) to develop and manufacture the British drugmaker’s COVID-19 vaccine candidate.

AstraZeneca in June picked Emergent to help produce the 300 million doses of its potential COVID-19 vaccine pledged to the United States.

Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below